Not Yet Recruiting NA INTERVENTIONAL 2-arm
NCT07185893
A Multicenter, Open-label, Randomized Controlled Trial Evaluating the Efficacy and Safety of Romiplostim N01 in the Treatment of Thrombocytopenia Associated With Concurrent/Sequential Chemoradiotherapy and Chemotherapy Combined With/Without Immunotherapy in Solid Tumors
Sponsor: Jun wang
Conditions
CTIT-Chemotherapy Induced Thrombocytopenia Solid Tumor Malignancies, Cancer Thrombocytopenia
Interventions
Human Interleukin-11 Romiplostim N01
Updated 1 time since 2025 Last updated: Sep 15, 2025 Started: Sep 30, 2025 Primary completion: Mar 1, 2028 Completion: Dec 31, 2028
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
Listed as NCT07185893, this NA trial focuses on CTIT-Chemotherapy Induced Thrombocytopenia and Solid Tumor Malignancies, Cancer and remains actively recruiting participants. Sponsored by Jun wang, it has been updated 1 time since 2025, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
1 version recorded Not Yet Recruiting — NA
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Jun wang
Data source: Hebei Medical University Fourth Hospital
For direct contact, visit the study record on ClinicalTrials.gov .